Stock Scorer

Atara Biotherapeutics, Inc. (ATRA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 35M 70M 105M Q1 '22: 7.3M Q2 '22: 51.6M Q3 '22: 4.5M Q4 '22: 221K Q1 '23: 1.2M Q2 '23: 957K Q3 '23: 2.1M Q4 '23: 4.3M Q1 '24: 27.4M Q2 '24: 28.6M Q3 '24: 40.2M Q4 '24: 32.8M Q1 '25: 98.1M Q2 '25: 17.6M Q3 '25: 3.5M Q4 '25: 1.6M Q1 '26: 516K Q2 '26: 630K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -84.8M Q4 '21: -93.4M Q1 '22: -88.2M Q2 '22: -32.1M Q3 '22: -84.6M Q4 '22: -75.5M Q1 '23: -75M Q2 '23: -71.4M Q3 '23: -69.6M Q4 '23: -60M Q1 '24: -31.2M Q2 '24: -18.2M Q3 '24: -21.8M Q4 '24: -12.2M Q1 '25: 38.8M Q2 '25: 3.2M Q3 '25: -3.6M Q4 '25: -2.6M Q1 '26: -3.4M Q2 '26: -4.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -84.7M Q4 '21: -93.3M Q1 '22: -88.1M Q2 '22: 18.5M Q3 '22: -84.1M Q4 '22: -74.6M Q1 '23: -74.8M Q2 '23: -71.1M Q3 '23: -69.8M Q4 '23: -60.5M Q1 '24: -31.8M Q2 '24: -19M Q3 '24: -21.9M Q4 '24: -12.7M Q1 '25: 38M Q2 '25: 2.4M Q3 '25: -4.3M Q4 '25: -3.4M Q1 '26: -4.1M Q2 '26: -4.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -59M Q4 '21: -34.3M Q1 '22: -84.5M Q2 '22: -64M Q3 '22: -65.1M Q4 '22: -56.9M Q1 '23: -38.4M Q2 '23: -52.8M Q3 '23: -51.3M Q4 '23: -50.4M Q1 '24: -29.6M Q2 '24: -10.6M Q3 '24: -4M Q4 '24: -24.5M Q1 '25: -28.1M Q2 '25: -7.3M Q3 '25: -9.8M Q4 '25: -5.7M Q1 '26: -3.1M Q2 '26: -3.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '21: -67.9M Q2 '21: -63.6M Q3 '21: -62.8M Q4 '21: -36.7M Q1 '22: -87.1M Q2 '22: -65.4M Q3 '22: -65.2M Q4 '22: -56.9M Q1 '23: -38.8M Q2 '23: -53.3M Q3 '23: -51.6M Q4 '23: -50.5M Q1 '24: -29.7M Q2 '24: -10.7M Q3 '24: -4M Q4 '24: -24.6M Q1 '25: -28.1M Q2 '25: -7.3M Q3 '25: -9.8M Q4 '25: -5.7M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '21: 92.2M Q3 '21: 93.6M Q1 '22: 100.7M Q2 '22: 101.9M Q3 '22: 102.4M Q1 '23: 104M Q2 '23: 4.2M Q3 '23: 4.3M Q1 '24: 5.6M Q2 '24: 6.1M Q3 '24: 7.5M Q1 '25: 10.9M Q2 '25: 12.3M Q3 '25: 13.6M Q1 '26: 14.1M Q2 '26: 15M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q3 '21: -3.61 Q4 '21: -3.63 Q1 '22: -3.64 Q2 '22: -2.55 Q3 '22: -2.47 Q4 '22: -2.24 Q1 '23: -2.09 Q2 '23: -19.18 Q3 '23: -34.76 Q4 '23: -47.95 Q1 '24: -52.88 Q2 '24: -39.07 Q3 '24: -25.60 Q4 '24: -11.75 Q1 '25: -2.60 Q2 '25: 0.69 Q3 '25: 3.30 Q4 '25: 2.57 Q1 '26: -1.22 Q2 '26: -1.73 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for ATRA: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.